Antitumour necrosis factor therapy in Crohn's disease (Q34974734)

5 August 2017

1 reference

title

Antitumour necrosis factor therapy in Crohn's disease (English)

1 reference

5 August 2017

0 references

2

Arthur Kaser

1 reference

5 August 2017

Herbert Tilg

1

1 reference

PubMed ID

12387670

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Expert Opinion on Biological Therapy

5 August 2017

1 reference

5 August 2017

2

1 reference

5 August 2017

7

1 reference

5 August 2017

715-721

1 reference

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

5 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

The relationship between infliximab treatment and lymphoma in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.7.715

21 January 2018

Identifiers

DOI

10.1517/14712598.2.7.715

1 reference

5 August 2017

1 reference

PubMed ID

12387670